Skip to main content
SpringerLink
Log in

Tissue Microarrays

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

High-throughput tissue microarray (TMA) technology facilitates the assessment of the clinical relevance of molecular markers by enabling the simultaneous analysis of hundreds of tissue specimens. The widespread adoption of TMAs in many laboratories replaces the conventional one-slide–one-section approach, in which individual archival clinical specimens were placed on separate microscope slides, with the ability to assess RNA, DNA, or protein expression in hundreds of individual patient specimens in a single experiment. One of the applications of this technology is to significantly accelerate advances in translational research through more efficient assessment of novel markers of outcome and response, and as a result, a more rapid application of this knowledge to clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Early Breast Cancer Trialists' Collaborative Group (2001). Tamoxifen for early breast cancer. Cochrane Database Syst. Rev. 1: CD000486.

    Google Scholar 

  2. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783–792.

    Google Scholar 

  3. J. Kononen, L. Bubendorf, A Kallioniemi, M. Bårlund, P. Schraml, S. Leighton, J. Torhorst, M. J. Mihatsch, G. Sauter, and O.-P. Kallioniemi (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4:844–847.

    Google Scholar 

  4. J. DeRisi, L. Penland, P. O. Brown, M. L. Bittner, P. S. Meltzer, M. Ray, Y. Chen, Y. A. Su, and J. M. Trent (1996). Use of a cDNA microarray to analyses gene expression patterns in human cancer. Nat. Genet. 14:457–460.

    Google Scholar 

  5. L. Bubendorf, M. Kolmer, J. Kononen, P. Koivisto, S. Mousses, Y. Chen, E. Mahlamaki, P. Schrami, H. Moch, N. Willi, A. G. Elkahloun, T. G. Pretlow, T. C. Gasser, M. J. Mihatsch, G. Sauter, and O.-P. Kallioniemi (1999). Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J. Natl. Cancer. Inst. 91:1758–1761.

    Google Scholar 

  6. H. Moch, P. Schraml, L. Bubendorf, M. Mirlacher, J. Kononen, T. Gasser, M. J. Mihatsch, O. P. Kallioniemi, and G. Sauter (1999). High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal carcinoma. Am. J. Pathol. 154:981–986.

    Google Scholar 

  7. M. Barland, F. Forozon, J. Kononen, L. Bubendorf, Y. Chen, M. L. Bittner, J. Torhorst, P. Haas, C. Bucher, G. Sauter, O.-P. Kallioniemi, and A. Kallioniemi (2000). Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 92:1252–1259.

    Google Scholar 

  8. S.-L. Sallinen, P. K. Sallinen, H. K. Haapasalo, H. J. Helin, P. T. Helen, P. Schraml, O. P. Kallioniemi, and J. Kononen (2000). Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60:6617–6622.

    Google Scholar 

  9. G. Callagy, E. Cattaneo, Y. Daigo, L. Happerfield, L. G. Bobrow, P. D. P. Pharoah, and C. Caldas (2003). Molecular classification of breast carcinomas using tissue microarrays. Diagn. Mol. Pathol. 12:27–34.

    Google Scholar 

  10. S. M. Dhanasekaran, T. R. Barrette, D. Ghosh, R. Shah, S. Varambally, K. Kurachi, K. J. Pienta, M. A. Rubin, and A. M. Chinnaiyan (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826.

    Google Scholar 

  11. S. Mousses, L. Bubendorf, U. Wagner, G. Hostetter, J. Kononen, R. Cornelison, N. Goldberger, A. G. Elkahloum, N. Willi, P. Koivisto, W. Ferhle, M. Raffeld, G. Sauter, and O. P. Kallioniemi (2002). Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 62:1256–1260.

    Google Scholar 

  12. J. B. Welsh, L. M. Sapinso, S. G. Kern, D. A. Brown, T. Liu, A. R. Bauskin, R. L. Ward N.J. Hawkins, D. I. Quinn, P. J. Russell, R. L. Sutherland, S. N. Breit, C. A. Moskaluk, H. F. Frierson, and G. M. Hampton (2003). Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. U.S.A. 100:3410–3415.

    Google Scholar 

  13. D. Gleason and G. Mellinger (1974). Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111:58–64.

    Google Scholar 

  14. A. Hoos and C. Cordon-Cardo (2001). Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab. Invest. 81:1331–1338.

    Google Scholar 

  15. R. L. Camp, L. A. Charette, and D. L. Rimm (2000). Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80:1943–1949.

    Google Scholar 

  16. A. Hoos, M. J. Urist, A. Stojadinovic, S. Mastorides, M. E. Dudas, D. H. Y. Leung, D. Kuo, M. F. Brennan, J. J. Lewis, and C. Cordon-Cardo (2001). Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol. 158:1245–1251.

    Google Scholar 

  17. N. R. Mucci, G. Akdas, S. Manely, M. A. Rubin (2000). Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein Expression. Hum. Pathol. 31:406–414.

    Google Scholar 

  18. S. M. Henshall, D. E. H. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, P. D. Stricker, H. Scher, J. J. Grygiel, D. Agus, D. H. Mack, and R. L. Sutherland (2003). Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196–4203.

    Google Scholar 

  19. N. MacIntyre (2001). Unmasking antigens for immunohistochemistry. Br. J. Biomed. Sci. 58:190–196.

    Google Scholar 

  20. C. L. Andersen, G. Hostetter, A. Grigoryan, G. Sauter, and A. Kallioniemi (2001). Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 45:83–86.

    Google Scholar 

  21. L. Bubendorf, J. Kononen, P. Koivisto, P. Schraml, H. Moch, T. C. Gasser, N. Willi, M. J. Mihatsch, G. Sauter, and O.-P. Kallioniemi (1999). Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridisation on tissue microarrays. Cancer Res. 59:803–806.

    Google Scholar 

  22. P. Schraml, J. Konenen, L. Bubendorf, H. Moch, H. Bissig, A. Nocito, M. J. Mihatsch, O.-P. Kallioniemi, and G. Sauter (1999). Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer Res. 5:1966–1975.

    Google Scholar 

  23. J. Richter, U. Wagner, J. Kononen, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurere, G. Alund, H. Knonagel, M. Rist, K. Wilber, M. Anabitarte, F. Hering, T. Hardmeier, A. Schonenberger, R. Flury, P. Jager, J. L. Fehr, P. Schraml, H. Moch, M. J. Mihatsch, T. Gasser, O. P. Kallioniemi, and G. Sauter (2000). High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol. 157:787–794.

    Google Scholar 

  24. E. E. Perrone, C. Theoharis, N. R. Mucci, S. Hayasaka, J. M. G. Taylor, K. A. Cooney, and M. A. Rubin (2000). Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J. Natl. Cancer Inst. 92:937–941.

    Google Scholar 

  25. M. A. Rubin, N. R. Mucci, J. Figurski, A. Fecko, K. J. Pienta, and M. L. Day (2001). E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Hum. Pathol. 32:690–697.

    Google Scholar 

  26. J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, O. R. Kochli, F. Mross, H. Dieterich, H. Moch, M. Mihatsch, O.-P. Kallioniemi, and G. Sauter (2001). Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159:2249–2256.

    Google Scholar 

  27. M. Schoenberg Fejzo and D. J. Slamon (2001). Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am. J. Pathol. 159:1645–1650.

    Google Scholar 

  28. S. Manley, N. R. Mucci, A. M. De Marzo, and M. A. Rubin (2001). Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome. Am. J. Pathol. 159:837–843.

    Google Scholar 

  29. L. Bubendorf, A. Nocito, H. Moch, and G. Sauter, (2001). Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 195:72–79.

    Google Scholar 

  30. R. L. Camp, M. Dolled-Filhart, B. L. King, and D. L. Rimm (2003). Quantitative analysis of breast cancer tissue microarrays show that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 63:1445–1448.

    Google Scholar 

  31. A. Coates (1998). International breast cancer study group trials. Recent Results Cancer Res. 152:429–440.

    Google Scholar 

  32. M. Colleoni, M. Boretti, A. S. Coates, M. Castiglione-Gertsch, R. D. Gelber, K. Price, C.-M. Rudenstam, J. Lindtner, J. Collins, B. Thurlimann, S. Holmberg, A. Veronesi, G. Marini, A. Goldhirsch (2000). Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J. Clin. Oncol. 18:584–590.

    Google Scholar 

  33. R. J. Cote, M. D. Dunn, S. J. Chatterjee, J. P. Stein, S. R. Shi, Q. C. Tran, S. X. Hu, H. J. Xu, S. Groshen, C. R. Taylor, D. G. Skinner, and W. F. Benedict (1998). Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58:1090–1094.

    Google Scholar 

  34. D. I. Quinn, S. M. Henshall, D. R. Head D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, J. J. Grygiel, P. D. Stricker, and R. L. Sutherland (2000). Prognostic significance of p53 nuclear accumulation in localised prostate cancer treated with radical prostatectomy. Cancer Res. 60:1585–1594.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales, 2010, Australia

    Susan Henshall

Authors
  1. Susan Henshall
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henshall, S. Tissue Microarrays. J Mammary Gland Biol Neoplasia 8, 347–358 (2003). https://doi.org/10.1023/B:JOMG.0000010034.43145.86

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JOMG.0000010034.43145.86

Search

Navigation